Current status of engineered T-cell therapy for synovial sarcoma Journal Article
| Authors: | Dallos, M.; Tap, W. D.; D'Angelo, S. P. |
| Article Title: | Current status of engineered T-cell therapy for synovial sarcoma |
| Abstract: | Synovial sarcoma is a rare soft tissue sarcoma characterized by a t(X;18) translocation, which results in a SYT-SSX gene fusion. In the metastatic setting, chemotherapy has limited, durable efficacy prompting the necessity for new therapeutic modalities. One emerging new strategy involves T-cell-directed therapy such as tumor-infiltrating lymphocytes or the development of T cells that are genetically engineered to express a T-cell receptor against a cancer testis antigen. Of these approaches, engineered T cells that recognize NY-ESO-1 are the furthest along in development. Completed and on-going clinical trials have shown promise and there are efforts to continue to optimize the current approach. © 2016 Future Medicine Ltd. |
| Keywords: | chimeric antigen receptor; synovial sarcoma; ny-eso-1; tumor-infiltrating lymphocytes; adoptive t-cell therapy; engineered t cell |
| Journal Title: | Immunotherapy |
| Volume: | 8 |
| Issue: | 9 |
| ISSN: | 1750-743X |
| Publisher: | Future Medicine |
| Date Published: | 2016-09-01 |
| Start Page: | 1073 |
| End Page: | 1080 |
| Language: | English |
| DOI: | 10.2217/imt-2016-0026 |
| PROVIDER: | scopus |
| PUBMED: | 27485079 |
| PMCID: | PMC5618931 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 September 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work